Loading asset research
Phathom Pharmaceuticals Inc. Common Stock
PHATNasdaq · USD · StocksQuote as of · Exchange session not verified$8.35
-0.24%
Today
PHAT
Loading 1D prices…
Market cap
$676.3M
Volume
1.4M
52w high
$18.3152w low
$8.07Company profile
Phathom Pharmaceuticals Inc. Common Stock
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Florham Park, NJ, United States
Employees
371
Fiscal year end
1231
CIK
1783183
Session & valuation
Open$8.40
Previous close$8.37
Day high$8.52
Day low$8.07
30-day avg. volume1.3M
Outstanding shares80.9M
Diluted EPS-$3.03
Latest annual period
P/E (trailing)-2.76
P/E (forward)7.77
Price / book-1.94
Beta0.51
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A Common Stock | $676.3M | $0.00 | — | -$1.58 | -1.67% | Buy |
| IRWDIronwood Pharmaceuticals Inc. Class A Common Stock | $674.2M | $296.2M | +8.11% | $0.15 | +2.77% | Buy |
| VSTMVerastem Inc. Common Stock | $662.9M | $30.9M | -677.59% | -$3.02 | -3.74% | Buy |
| COLLCollegium Pharmaceutical Inc. Common Stock | $705.2M | $780.6M | +8.07% | $1.73 | -0.83% | Buy |
| NGNENeurogene Inc. Common Stock | $710M | $0.00 | — | -$4.24 | -1.77% | Buy |